Literature DB >> 12133983

Bystander CD8 T cell-mediated demyelination after viral infection of the central nervous system.

Jodie S Haring1, Lecia L Pewe, Stanley Perlman.   

Abstract

Multiple sclerosis, a chronic inflammatory disease of the CNS, is characterized by immune-mediated demyelination. Many patients have a remitting-relapsing course of disease with exacerbations often following unrelated microbial illnesses. The relationship between the two events remains obscure. One possibility is that T cells specific for the inciting microbial pathogen are able to effect demyelination at a site of ongoing inflammation within the CNS. This possibility was examined in mice infected with mouse hepatitis virus, a well-described model of virus-induced demyelination. Using transgenic TCR/recombination activation gene 2(-/-) mice with only non-mouse hepatitis virus-specific T cells, we show that CD8 T cells are able to cause demyelination in the absence of cognate Ag in the CNS, but only if specifically activated. These findings demonstrate a novel mechanism for immune-mediated neuropathology and show that activated CD8 T cells may serve as important mediators of bystander demyelination during times of infection, including in patients with multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133983     DOI: 10.4049/jimmunol.169.3.1550

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

2.  Virally activated CD8 T cells home to Mycobacterium bovis BCG-induced granulomas but enhance antimycobacterial protection only in immunodeficient mice.

Authors:  Laura H Hogan; Dominic O Co; Jozsef Karman; Erika Heninger; M Suresh; Matyas Sandor
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

3.  Virus-specific and bystander CD8 T cells recruited during virus-induced encephalomyelitis.

Authors:  Audrey M Chen; Nivedita Khanna; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Immune regulatory mechanisms influence early pathology in spinal cord injury and in spontaneous autoimmune encephalomyelitis.

Authors:  Maria Cecilia G Marcondes; Glaucia C Furtado; Allen Wensky; Maria A Curotto de Lafaille; Howard S Fox; Juan J Lafaille
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

5.  Increased epitope-specific CD8+ T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination.

Authors:  Katherine C MacNamara; Ming Ming Chua; Peter T Nelson; Hao Shen; Susan R Weiss
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 6.  The role of bystander T cells in CNS pathology and pathogen clearance.

Authors:  Dorian B McGavern
Journal:  Crit Rev Immunol       Date:  2005       Impact factor: 2.214

7.  Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus.

Authors:  Taeg S Kim; Stanley Perlman
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  A mechanism of virus-induced demyelination.

Authors:  Jayasri Das Sarma
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-06-21

9.  Rebuilding an immune-mediated central nervous system disease: weighing the pathogenicity of antigen-specific versus bystander T cells.

Authors:  Dorian B McGavern; Phi Truong
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

10.  Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia.

Authors:  Yun Li; Li Fu; Donna M Gonzales; Ehud Lavi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.